# Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

> **NCT04903626** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 286 (actual)

## Conditions studied

- Hepatitis C Virus (HCV)

## Interventions

- **DRUG:** Glecaprevir/Pibrentasvir (GLE/PIB)

## Key facts

- **NCT ID:** NCT04903626
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-24
- **Primary completion:** 2024-09-17
- **Final completion:** 2024-09-17
- **Target enrollment:** 286 (ACTUAL)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04903626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04903626, "Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04903626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*